Nektar Therapeutics (NASDAQ:NKTR) CFO Gil M. Labrucherie Sells 25,000 Shares of Stock

Nektar Therapeutics (NASDAQ:NKTR) CFO Gil M. Labrucherie sold 25,000 shares of the business’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $17.79, for a total transaction of $444,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Gil M. Labrucherie also recently made the following trade(s):

  • On Wednesday, July 10th, Gil M. Labrucherie sold 25,000 shares of Nektar Therapeutics stock. The shares were sold at an average price of $34.57, for a total transaction of $864,250.00.
  • On Monday, June 17th, Gil M. Labrucherie sold 25,000 shares of Nektar Therapeutics stock. The shares were sold at an average price of $33.71, for a total transaction of $842,750.00.

NASDAQ NKTR opened at $18.10 on Friday. The company has a current ratio of 14.09, a quick ratio of 14.83 and a debt-to-equity ratio of 0.22. The company has a 50 day moving average price of $30.42 and a 200 day moving average price of $34.20. Nektar Therapeutics has a 52 week low of $17.30 and a 52 week high of $69.76.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.17. The firm had revenue of $23.32 million during the quarter, compared to analyst estimates of $26.65 million. Nektar Therapeutics had a negative net margin of 354.90% and a negative return on equity of 25.25%. Nektar Therapeutics’s revenue was down 97.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.33 EPS. As a group, equities analysts forecast that Nektar Therapeutics will post -2.93 EPS for the current year.

Several equities research analysts have recently commented on NKTR shares. ValuEngine upgraded shares of Nektar Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. HC Wainwright restated a “hold” rating on shares of Nektar Therapeutics in a report on Tuesday. TheStreet lowered shares of Nektar Therapeutics from a “c” rating to a “d” rating in a report on Thursday, August 8th. Zacks Investment Research lowered shares of Nektar Therapeutics from a “buy” rating to a “hold” rating and set a $34.00 price target for the company. in a report on Wednesday, July 31st. Finally, William Blair restated a “buy” rating on shares of Nektar Therapeutics in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $49.15.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Verition Fund Management LLC acquired a new position in Nektar Therapeutics during the second quarter worth $254,000. Ladenburg Thalmann Financial Services Inc. raised its position in shares of Nektar Therapeutics by 17.6% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 24,195 shares of the biopharmaceutical company’s stock valued at $861,000 after buying an additional 3,615 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its position in shares of Nektar Therapeutics by 9.2% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 14,520 shares of the biopharmaceutical company’s stock valued at $517,000 after buying an additional 1,219 shares during the last quarter. Voloridge Investment Management LLC acquired a new stake in shares of Nektar Therapeutics in the second quarter valued at about $3,284,000. Finally, Pictet Asset Management Ltd. raised its position in shares of Nektar Therapeutics by 167.8% in the second quarter. Pictet Asset Management Ltd. now owns 226,021 shares of the biopharmaceutical company’s stock valued at $8,042,000 after buying an additional 141,621 shares during the last quarter. Hedge funds and other institutional investors own 92.48% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Featured Article: Mutual funds are not immune from market timing

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit